CENTANY (mupirocin) by Design Pharmaceuticals is clinical pharmacology following the application of centany (mupirocin ointment),2% to a 400 cm area on the back of 23 healthy volunteers once daily for 7 days, the mean (range) cumulative urinary excretion of monic acid over 24 hrs following the last administration was 1. First approved in 2002.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
Centany (mupirocin) is a topical antibiotic ointment that inhibits bacterial protein synthesis by binding to isoleucyl-tRNA synthetase, making it bactericidal against gram-positive bacteria including S. aureus and S. pyogenes. It is indicated for skin infections caused by susceptible strains and is applied directly to affected areas. The unique mechanism of action prevents cross-resistance with other antimicrobial classes, though plasmid-mediated resistance is increasingly observed.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team consolidation and transition focus.
CLINICAL PHARMACOLOGY Following the application of Centany (mupirocin ointment),2% to a 400 cm area on the back of 23 healthy volunteers once daily for 7 days, the mean (range) cumulative urinary excretion of monic acid over 24 hrs following the last administration was 1.25% (0.2% to 3.0%) of the…
Worked on CENTANY at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU
Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)
Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants
Impact of Mupirocin Decolonization on the Nasal Microbiome
Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin
Working on Centany offers experience in mature portfolio management and topical antibiotic commercial strategy, but limited opportunity for high-growth career acceleration. The approaching LOE and moderate competitive pressure suggest roles focus on maximizing remaining exclusivity value and managing transition to generic competition.